Clot in Transit: A Therapeutic Dilemma

Patel, Mayankbhai; Raza, Ali; Murabia, A.; Patel, Sapan; Russi, Thomas

doi:10.1016/j.chest.2017.08.1056

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When CIT is coupled with intermediate-risk PE, there is a very high mortality rate with no morbidity benefit when comparing treatment choices. Recent studies on CIT report mortality rates associated with various methods as follows: no therapy, anticoagulation therapy, surgical embolectomy, and thrombolysis at 100%, 28.6%, 23.8%, and 11.3% respectively [ 3 ]. Additionally, there has been no observable difference in long-term mortality among patients with intermediate-risk pulmonary emboli when comparing thrombolysis and anticoagulation alone as most deaths occur within 30 days of the original event [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Clot in Transit: Therapy via Peripherally Inserted Central Catheter Line

Mustafa¹,

Obholz²,

Ghanim³

et al. 2022

Cureus

View full text Add to dashboard Cite

There are currently no definitive guidelines for the optimal management of clots in transit (CIT) due to a distinct lack of quality research to suggest a recommended therapy. The three main treatment modalities that are commonly utilized for pulmonary emboli (PE) (a sequela of CIT) are thrombolysis, pulmonary embolectomy, and anticoagulation alone. The current recommendation for severe PE with hemodynamic collapse is to consult cardiothoracic surgery for clot retrieval. One ongoing area of research involves the use of catheter-directed application of thrombolytic agents as it may have similar outcomes to the systemic application while minimizing the risk of bleeding events due to a lower dose of medication used. We report the case of a patient in whom, by taking advantage of an already placed peripherally inserted central catheter (PICC) line, tissue plasminogen activator (tPA) was successfully delivered at a localized site near the clot for active thrombolysis while only causing minimal adverse effects related to recent laminectomy/fasciectomy and foraminotomy compared to what may have been observed with systemic tPA administration.

show abstract

Section: Discussionmentioning

confidence: 99%